Информативни материјали

/content/dam/roche_macedonia/mk_MK/documents/haemophilia_a_infographic mkd.pdf

Референци:

  1. Flood E, et al. Illustrating the impact of mild/moderate and severe haemophilia on health-related quality of life: hypothesised conceptual models. European Journal of Haematology 2014; 93: Suppl. 75, 9–18. 
  2. WFH. Guidelines for the management of hemophilia. 2012. Пристапено: 24 мај 2017: http://www1.wfh.org/publications/files/ pdf-1472.pdf.
  3. Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet 2012; 370:1447-1456. 
  4. Marder VJ, et al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin. 
  5. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013:179–84. 
  6. Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program 2012; 2012: 362–8.
  7. Zanon E, Iorio A, Rocino A, et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia 2012; 18: 39–45. 
  8. Chen SL. Economic Costs of Hemophilia and the Impact of Prophylactic Treatment on Patient Management. AJMC 2016; 22 (5): 126-133. 
  9. Elder-Lissai A, Hou Q, Krishnan S. The Changing Costs of Caring for Hemophilia Patients in the U.S.: Insurers’ and Patients’ Perspectives. Presented at: American Society of Hematology Annual Meeting; De-cember 6-9, 2014; San Francisco, CA. Abstract #199. 
  10. Remor E. Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients. Haemophilia 2011; 17, e901–e905. 
  11. Hacker MR, et al. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001; 7: 392-6. 
  12. Ljung R. The risk associated with indwelling catheters in children with haemophilia. British Journal of Haematology 2007; 138: 580–586. 
  13. Gomez K, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014; 12: s319–s329. 
  14. Whelan SF, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039–48. 
  15. Astermark J. Overview of Inhibitors. Semin Hematol 2006; 43 (suppl 4):S3-S7. 
  16. Rocino A, et al. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2015: 10. 
  17. Mancuso ME, et al. US Immune tolerance induction in haemophilia. Clinical Investigation. 2015; 5(3), 321–335. 
  18. Berntorp, E. Dif-ferential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009; 15: 3-10.